Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06316830 · ClinicalTrials.gov registry record · Phase 2

Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose

A Phase 2 study of Opioid Use Disorder, sponsored by Rhode Island Hospital.

Recruiting
Registry status
Phase 2
Development phase
250
Enrollment target
1
Study location

NCT06316830 is a Phase 2 study of Opioid Use Disorder that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 250 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06316830, a Phase 2 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Rhode Island Hospital.

RECRUITING
Registry status
Phase 2
Development phase
250 participants
Enrollment target
1
Study location

Study Summary

The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment response based on use of non-prescribed opioids (secondary outcome), decreased opioid cravings (secondary outcome), and decreased risk of fatal and non-fatal opioid overdose (exploratory outcome).

Conditions Studied

Opioid Use Disorder

Interventions

  • DRUG Buprenorphine

Study Locations (1)

Rhode Island

  • Brown University - Providence

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-01-06
Est. Completion 2027-11-01
Phase Phase 2

Sponsor

Rhode Island Hospital

130 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06316830

The ClinicalTrials.gov registry entry for NCT06316830 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine is the first listed.

NCT06316830 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT06316830 about?

NCT06316830 is a clinical study titled "Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose". The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg). The main question it aims to answer is: will patients who are randomly assigned to the high ...

What is the current status of trial NCT06316830?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-01-06. Estimated completion is 2027-11-01.

What conditions does trial NCT06316830 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06316830?

The interventions under investigation include: Buprenorphine (DRUG).

Who is sponsoring clinical trial NCT06316830?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06316830 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Opioid Use Disorder

All registered trials for this condition

Rhode Island

All trials with a study site in Rhode Island

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.